TP53 and acute myeloid leukemia: Our results imply that the favorable clinical response of patients with TP53 mutations to decitabine is not the direct consequence of p53 dysfunction, but is likely due to secondary genetic/epigenetic alterations provoked by p53 dysfunction in MDS/AML cells.